Prior to forming his own consulting practice, Dr. DeCillis was the Chief Medical Officer for Eleven Biotherapeutics (now Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Previous roles in oncology drug development included Vice President of Clinical Research and then Vice President of Medical Affairs at Exelixis, Inc., an oncology- focused biotechnology company, Executive Director of Oncology Development at Novartis and Group Director of Bristol-Myers Squibb. Dr. DeCillis has been involved in the development of several commercialized oncology drugs including SPRYCEL® (dasatinib), AFINITOR® (everolimus), FARYDAK® (panobinostat), and CABOMETYX® (cabozantinib). He holds an M.D. from University of Rochester and completed an internal medicine residency at Medical College of Virginia and a fellowship at University of Pittsburgh.